Dexcom launches data sharing in cloud-based diabetes management

dexcom g5 system including cell phone and app
Dexcom Mobile G5 CGM system--Courtesy of Dexcom

Dexcom ($DXCM) unveiled new data-sharing capabilities for its cloud-based diabetes management platform, Clarity.

Now, patients and physicians may easily share data with each other, according to a Dexcom statement. The platform automatically sends patient data from the Dexcom G5 continuous glucose monitor to a secure cloud-based system that his or her physician can access.

The new clinic portal integrates into the existing Clarity infrastructure, so physicians will have access to retrospective CGM blood glucose data. To start using data sharing, physicians will use the platform to generate an email inviting patients to securely share their CGM data. On accepting the invitation, patients will be connected to their physician’s office and automatic data sharing via the Dexcom G5 mobile app or a computer will commence, Dexcom said.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"DexCom CLARITY simplifies the interpretation of CGM-generated data and allows for automated summaries and insights for physicians, empowering them to assess if a diabetes treatment plan is working,"  said Dexcom CEO Kevin Sayer, in the statement.

In addition to informing clinicians’ diabetes management decisions, Clarity also gives patients a better understanding of their CGM data. The upgrade includes an interactive “overlay” graph, which puts glucose data in a weekly overview, allowing the patient to visualize the frequency, duration and intensity of their hypo- and hyperglycemia patterns.

Dexcom has been on a roll of late, last week dropping details on its in-development G6 CGM and partnership with Verily on its Q2 earnings call. And just last month, the San Diego-based company picked up an FDA nod for the use of its G5 monitor as an alternative to fingerstick glucose testing to inform treatment decisions.

- here's the statement

Related Articles:
Dexcom talks non-fingerstick CGM, Verily deal
FDA panel gives Dexcom’s G5 continuous glucose monitor favorable vote
Google's Verily, Dexcom aim to launch mini glucose monitor in 2018, with next-gen by 2021

Read more on

Suggested Articles

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.